OABI_OUT_1 [2025-04-14 15:10:16 -0400] 3062 Bytes | 758 tokens | Cum: 758 tkns (9.47% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at OmniAb (OABI) which is at 1.9250 up from 1.9300. So, I pulled together a bunch of data for you to look over real fast. It's still early, 3:10:15 PM on Mon Apr 14, 2025 -0400. So, what's the verdict? You're the expert!

--- COMPANY PROFILE ---
Company: OmniAb (OABI)
IPO: 2022-11-01 (2 Years Ago)
Market Cap: $238,163,135
Shares Outstanding: 122,140,000
Industry: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Exchange: XNAS
Description: OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.

Here’s the first list of news for OmniAb:

C1 - Today 08:00AM - OmniAb to Report First Quarter 2025 Financial Results on May 8
C2 - Mar-18-25 04:05PM - OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
C3 - Feb-24-25 08:00AM - OmniAb to Report Fourth Quarter 2024 Financial Results on March 18
C4 - Feb-03-25 04:57PM - OmniAb to Participate in Two Investor Conferences in March
C5 - Dec-16-24 04:15PM - OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering and Therapeutics Conference
C6 - Nov-12-24 04:05PM - OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights
C7 - Oct-30-24 08:00AM - OmniAb to Participate in Two Investor Conferences in November
C8 - Oct-22-24 08:00AM - OmniAb to Report Third Quarter 2024 Financial Results on November 12

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and report parser.
Your role is to examine all available company data and draw sound conclusions.
The company under analysis is: OmniAb (OABI).

2) To request information, refer to any listed documents using their reference codes.

3) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs:

Restrict all your responses to just 3 tokes until it's time for the summary and data pairs at the end.
Request a document with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

OABI_OUT_3 [2025-04-14 15:10:17 -0400] 251 Bytes | 78 tokens | Cum: 839 tkns (10.49% of 8k)
==========================================================================

You just read a chunk of A1.
You may now:
- Say "MOR" to continue this article
- Say "A2", "A3", etc. to request another
- Or say "NEX" to move to the next source

You are allowed up to 3 articles from this list. If you’re ready to move on, say NEX.

OABI_OUT_5 [2025-04-14 15:10:17 -0400] 889 Bytes | 293 tokens | Cum: 1135 tkns (14.19% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-10T02:27:35Z - Insider Selling: OmniAb, Inc. (NASDAQ:OABI) Insider Sells 7,206 Shares of Stock...
A2 - 2025-04-10T02:27:33Z - Insider Selling: OmniAb, Inc. (NASDAQ:OABI) CEO Sells $38,764.00 in Stock...
A3 - 2025-04-09T11:12:46Z - ADAR1 Capital Management LLC Has $985,000 Stock Position in OmniAb, Inc. (NASDAQ:OABI)...
A4 - 2025-04-09T09:03:53Z - OmniAb, Inc. (NASDAQ:OABI) CEO Matthew W. Foehr Sells 19,382 Shares...
A5 - 2025-04-09T08:20:34Z - OmniAb (OABI) Receives a Buy from RBC Capital...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

OABI_OUT_7 [2025-04-14 15:10:18 -0400] 1098 Bytes | 319 tokens | Cum: 1456 tkns (18.20% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**Insider Selling: OmniAb, Inc. (NASDAQ:OABI) Insider Sells 7,206 Shares of Stock**Date: 2025-04-10Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/insider-selling-omniab-inc-nasdaqoabi-insider-sells-7206-shares-of-stock-2025-04-07/OmniAb, Inc. (NASDAQ:OABI - Get Free Report) insider Charles S. Berkman sold 7,206 shares of OmniAb stock in a transaction dated Monday, April 7th. The stock was sold at an average price of $2.00, for a total value of $14,412.00. Following the transaction, the insider now directly owns 363,212 shares in the company, valued at approximately $726,424. The trade was a 1.95 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of OmniAb stock remained fla

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

OABI_OUT_9 [2025-04-14 15:10:19 -0400] 1098 Bytes | 325 tokens | Cum: 1783 tkns (22.29% of 8k)
==========================================================================

Showing A1 (chunk 2 of 5): t at $2.09 during trading on Monday. 979,679 shares of the stock traded hands, compared to its average volume of 553,387. OmniAb, Inc. has a 1-year low of $1.91 and a 1-year high of $5.45. The stock's 50-day simple moving average is $3.14 and its 200 day simple moving average is $3.61. The stock has a market cap of $255.26 million, a P/E ratio of -3.37 and a beta of 0.06.

OmniAb (NASDAQ:OABI - Get Free Report) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.01. OmniAb had a negative net margin of 308.78% and a negative return on equity of 20.97%. The firm had revenue of $10.80 million during the quarter, compared to analyst estimates of $10.13 million. During the same quarter last year, the business posted ($0.14) EPS. On average, sell-side analysts predict that OmniA

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

OABI_OUT_11 [2025-04-14 15:10:20 -0400] 845 Bytes | 293 tokens | Cum: 2106 tkns (26.32% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-04-30T21:55:12Z - USANA Health Sciences (USNA) Q1 Earnings and Revenues Top Estimates
B2 - 2024-03-26T12:40:44Z - Over $1M Bet On OmniAb? Check Out These 3 Stocks Insiders Are Buying
B3 - 2024-03-05T22:35:03Z - Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
B4 - 2024-02-29T13:40:05Z - Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
B5 - 2024-02-28T13:27:00Z - OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock?
B6 - 2024-02-27T14:35:02Z - Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

OABI_OUT_13 [2025-04-14 15:10:25 -0400] 615 Bytes | 183 tokens | Cum: 2291 tkns (28.64% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**USANA Health Sciences (USNA) Q1 Earnings and Revenues Top Estimates**Date: Unknown DateSource: Unknown SourceURL: https://www.zacks.com/stock/news/2265479/usana-health-sciences-usna-q1-earnings-and-revenues-top-estimatesUSANA Health (USNA) delivered earnings and revenue surprises of 24.64% and 2.03%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

OABI_OUT_15 [2025-04-14 15:10:25 -0400] 805 Bytes | 198 tokens | Cum: 2588 tkns (32.35% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S7 - 2025-03-18 8-K Item 2.02 Results of Oper and Fin Cond.

On March 18, 2025, OmniAb Inc. (the Company) issued a press release announcing its financial results for the three months and full year ended December 31, 2024. A copy of this press release is furnished herewith as Exhibi...

S8 - 2025-03-18 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes included elsewhere i...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

OABI_OUT_17 [2025-04-14 15:10:33 -0400] 1023 Bytes | 262 tokens | Cum: 2852 tkns (35.65% of 8k)
==========================================================================

Showing S7 (chunk 1 of 1): S7:
Item 2.02 Results of Operations and Financial Condition.

On March 18, 2025, OmniAb Inc. (the Company) issued a press release announcing its financial results for the three months and full year ended December 31, 2024. A copy of this press release is furnished herewith as Exhibit 99.1 to this report.

In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing....

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

OABI_OUT_19 [2025-04-14 15:10:41 -0400] 7749 Bytes | 2240 tokens | Cum: 5252 tkns (65.65% of 8k)
==========================================================================

This is our set of metrics for OmniAb.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+------------------------+
| Volume: 1,067,429 | Perf Month: -41.39% | Option/Short: Yes / Yes | Sales Y/Y TTM: -22.75% |
+---------------------+-----------------------+-------------------------+------------------------+
| Avg Volume: 672.03K | Perf Quarter: -41.92% | Short Float: 9.27% | ROE: -20.60% |
+---------------------+-----------------------+-------------------------+------------------------+
| Rel Volume: 1.89 | Index: RUT | Short Ratio: 13.49 | ROI: -20.21% |
+---------------------+-----------------------+-------------------------+------------------------+
| RSI (14): 28.97 | Market Cap: 234.76M | Short Interest: 9.07M | Sales Surprise: 6.69% |
+---------------------+-----------------------+-------------------------+------------------------+
| ATR (14): 0.17 | Shs Outstand: 121.60M | Beta: 0.18 | EPS Surprise: -18.46% |
+---------------------+-----------------------+-------------------------+------------------------+
| SMA20: -15.38% | Shs Float: 97.79M | Sales Q/Q: 124.06% | P/E: - |
+---------------------+-----------------------+-------------------------+------------------------+
| SMA50: -35.44% | Inst Own: 53.57% | Sales past 5Y: 1.70% | Earnings: Mar 18 AMC |
+---------------------+-----------------------+-------------------------+------------------------+
| SMA200: -48.57% | Insider Own: 19.19% | Employees: 114 | |
+---------------------+-----------------------+-------------------------+------------------------+
| Perf Week: -7.18% | Insider Trans: -0.43% | Debt/Eq: 0.08 | |
+---------------------+-----------------------+-------------------------+------------------------+

The next section covers any insider trading by OmniAb officers or majority shareholders (if available).

Inside Trans: OmniAb, Inc. (OABI) by FOEHR MATTHEW W (President and CEO) on 2025-04-07
- Common Stock: 36458 shares at $0 (D)
- Common Stock: 19382 shares at $2 (D)
- Restricted Stock Units: 36458 shares at $0 (D)

Inside Trans: OmniAb, Inc. (OABI) by Berkman Charles S (Chief Legal Officer) on 2025-04-07
- Common Stock: 13542 shares at $0 (D)
- Common Stock: 7206 shares at $2 (D)
- Restricted Stock Units: 13542 shares at $0 (D)

Inside Trans: OmniAb, Inc. (OABI) by GUSTAFSON KURT A (Executive VP, Finance and CFO) on 2025-04-07
- Common Stock: 13542 shares at $0 (D)
- Common Stock: 7206 shares at $2 (D)
- Restricted Stock Units: 13542 shares at $0 (D)

Inside Trans: OmniAb, Inc. (OABI) by GUSTAFSON KURT A (Executive VP, Finance and CFO) on 2025-04-01
- Common Stock: 23244 shares at $0 (D)
- Common Stock: 11963 shares at $2.37 (D)
- Restricted Stock Units: 23244 shares at $0 (D)

Inside Trans: OmniAb, Inc. (OABI) by HIGGINS JOHN L (Unknown Title) on 2025-03-21
- Common Stock: 4000 shares at $2.28 (D)

Inside Trans: OmniAb, Inc. (OABI) by HIGGINS JOHN L (Unknown Title) on 2025-03-20
- Common Stock: 125750 shares at $2.35 (D)

Inside Trans: OmniAb, Inc. (OABI) by Berkman Charles S (Chief Legal Officer) on 2025-02-15
- Common Stock: 15615 shares at $N/A (D)
- Common Stock: 13541 shares at $N/A (D)
- Common Stock: 8215 shares at $3.68 (D)
- Common Stock: 7255 shares at $3.67 (D)
- Restricted Stock Units: 15615 shares at $0 (D)
- Restricted Stock Units: 13541 shares at $0 (D)
- Restricted Stock Units: 56250 shares at $0 (D)
- Stock Option (right to buy): 337500 shares at $0 (D)

Inside Trans: OmniAb, Inc. (OABI) by FOEHR MATTHEW W (President and CEO) on 2025-02-15
- Common Stock: 26549 shares at $N/A (D)
- Common Stock: 36458 shares at $N/A (D)
- Common Stock: 13964 shares at $3.68 (D)
- Common Stock: 19522 shares at $3.67 (D)
- Restricted Stock Units: 26549 shares at $0 (D)
- Restricted Stock Units: 36458 shares at $0 (D)
- Restricted Stock Units: 175000 shares at $0 (D)
- Stock Option (right to buy): 1050000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 26391000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -62033000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.92
Average Volume: 946323.0
30-Day High: 3.19
30-Day Low: 1.85

[Detailed Financials: TTM 2024]
- Total Assets: $325,558,000.0
- Total Liabilities: $37,940,000.0
- Total Equity: $287,618,000.0
- Current Assets: $68,138,000.0
- Current Liabilities: $15,088,000.0

[Income Statement: TTM 2024]
- Revenue: $26,391,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.61

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $11,240,000.0

[Detailed Financials: FY 2024]
- Total Assets: $325,558,000.0
- Total Liabilities: $37,940,000.0
- Total Equity: $287,618,000.0
- Current Assets: $68,138,000.0
- Current Liabilities: $15,088,000.0

[Income Statement: FY 2024]
- Revenue: $26,391,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.61

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $11,240,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of OmniAb (OABI).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about OmniAb.

2) MARKET_SCORE[]
This conversation was initiated because OABI is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for OABI.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, OABI could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect OABI to increase 50% from its current price of $1.92, say: PRICE_TARGET[2.89]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of OmniAb.

11) ETHICAL_RATING[]
Rate OmniAb’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

Return only: FIELD[value] for each of the above 11 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

OABI_IN_21 [2025-04-14 15:10:41 -0400] 126 Bytes | 29 tokens | Cum: 5479 tkns (68.49% of 8k)
==========================================================================

====================================
[2025-04-14 15:10:41] # Analysis Completed
Elapsed Time: 26.56 seconds